FourThought Financial Partners LLC Sells 98 Shares of Novo Nordisk A/S (NYSE:NVO)

FourThought Financial Partners LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 1.8% in the 4th quarter, Holdings Channel reports. The firm owned 5,463 shares of the company’s stock after selling 98 shares during the quarter. FourThought Financial Partners LLC’s holdings in Novo Nordisk A/S were worth $565,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Pacific Center for Financial Services increased its position in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Bell Investment Advisors Inc raised its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after buying an additional 127 shares in the last quarter. CNB Bank bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $26,000. Citizens National Bank Trust Department grew its position in Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after acquiring an additional 150 shares in the last quarter. Finally, Tyler Stone Wealth Management increased its stake in Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after acquiring an additional 146 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 0.8 %

Shares of NYSE:NVO traded down $0.97 during trading on Friday, reaching $123.05. 5,932,926 shares of the company traded hands, compared to its average volume of 3,905,318. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The firm has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a P/E/G ratio of 2.06 and a beta of 0.43. The business’s fifty day moving average is $127.20 and its 200-day moving average is $113.10.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 92.21%. The business had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. As a group, analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on NVO shares. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.